RNA-protein interactions play critical roles in cellular regulatory processes and in the life cycles of many pathogenic viruses including HIV, hepatitis C, SARS, and West Nile virus, and thus represent attractive targets for therapeutics. We have developed novel cell-based assays to identify drugs that target the RNA-protein interactions. The assays incorporate a system of genetic reporters to accurately recapitulate RNA-protein interactions and enable screens with high sensitivity and specificity. In an initial test of the system, the HIV Rev-RRE interaction was successfully targeted with control inhibitors of the RNA-protein interaction. Experiments to optimize and convert the drug screening assays to high throughput format are currently in progress. The assays will be tested by screening a combinatorial library of RRE-binding peptides to be followed by a high-throughput chemical compound library screen. The development of high-throughput genetic methods to identify specific inhibitors of RNA-protein interactions is expected to help in the discovery of drugs directed against novel therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Technology Transfer (STTR) Grants - Phase II (R42)
Project #
2R42CA103407-02
Application #
6932178
Study Section
Special Emphasis Panel (ZRG1-GGG-J (10))
Program Officer
Daschner, Phillip J
Project Start
2003-09-12
Project End
2007-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
2
Fiscal Year
2005
Total Cost
$419,572
Indirect Cost
Name
Advanced Genetic Systems, Inc.
Department
Type
DUNS #
154446921
City
San Francisco
State
CA
Country
United States
Zip Code
94122
Nakamura, Robert L; Burlingame, Mark A; Yang, Shumin et al. (2017) Identification and Optimization of Thienopyridine Carboxamides as Inhibitors of HIV Regulatory Complexes. Antimicrob Agents Chemother 61: